| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | A proposal for integrating intraductal carcinoma of the prostate into pathological T substaging. |
| 掲載誌名 | 正式名：Prostate international 略 称：Prostate Int ISSNコード：22878882/22878882 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 14(2),pp.169-172 |
| 著者・共著者 | Remi Semba, Katsunori Uchida, Takeshi Sasaki, Takahiro Inoue, Hiroshi Miyamoto |
| 発行年月 | 2026/06 |
| 概要 | BACKGROUND:The present study aims primarily to determine how incorporation of intraductal carcinoma of the prostate (IDCP) detected in radical prostatectomy (RP) specimens into pathological T (pT) impacts patient outcomes.METHODS:The study included 1,190 patients who had undergone RP at Mie University Hospital (Tsu, Mie, Japan) from 2015 to 2023 (n = 470) and at the University of Rochester Medical Center (Rochester, NY, USA) from 2010 to 2011 (n = 720). The risks of biochemical recurrence (BCR) were compared in RP patients with or without IDCP according to the pT stage (i.e., pT2/IDCP+, pT2/IDCP-, pT3a/IDCP+, pT3a/IDCP-, pT3b/IDCP+, and pT3b/IDCP-).RESULTS:The prognosis of the pT2/IDCP group was significantly better than that of the other groups (P < 0.001). Meanwhile, there was no statistically significant difference in BCR between pT2/IDCP+ and pT3a/IDCP- (P = 0.548). In pT3b patients, IDCP had no additional prognostic impact.CONCLUSIONS:IDCP in pT2 and pT3a cases was strongly associated with the risk of BCR. In addition, the prognosis for pT2/IDCP + versus pT3a/IDCP- or pT3b/IDCP- versus pT3b/IDCP+ was comparable. These findings indicate that IDCP may confer a BCR risk comparable to that of extraprostatic extension in pT2 cases but its prognostic impact appears limited in pT3b disease. |
| DOI | 10.1016/j.prnil.2026.01.003 |
| PMID | 42382559 |